Opinion|Videos|October 11, 2024
Meningococcal Infection and NMOSD
Author(s)Sean Pittock, MD
Key Takeaways
- Eculizumab and ravulizumab increase meningococcal infection risk, necessitating vaccination in treated patients.
- Phase 3 and long-term studies emphasize the need for vigilant monitoring and prophylactic measures despite vaccination.
Sean Pittock, MD, discusses the risks of meningococcal infection associated with eculizumab and ravulizumab in phase 3 and long-term extension studies, as well as his interpretation of the concerns surrounding meningococcal vaccination and its potential impact on relapse activity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Discuss the risk of meningococcal infection with eculizumab and ravulizumab in phase 3 and long-term extension studies.
- There may be concerns with meningococcal vaccination and its impact on relapse activity. What is your interpretation of these data?
Advertisement
Related to this article
The FDA extended its review of relutrigine for SCN2A- and SCN8A-related epilepsies by three months, pushing the PDUFA date to December 27, 2026.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is clinical trial results in Alzheimer disease!
In recognition of International Ataxia Awareness Day, observed annually on September 25, NeurologyLive® reviews 6 investigational agents in clinical development across ataxia-related disorders.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending September 25, 2026.
MS Compass: Guiding Clinical Care, a podcast hosted by neuroimmunologist Lindsay Ross, MD, brings you an exclusive interview with Rachel Galioto, PhD. [LISTEN TIME: 33 minutes]
A. Blake Buletko, MD, and Galina Gheihman, MD, discuss their career paths in neurology, the role of mentorship and resilience, and strategies for navigating professional growth as early-career clinician-educators.
One-year KYSA-6 data showed KYV-101, a CD19 CAR T-cell therapy, produced durable, drug-free responses in generalized myasthenia gravis.
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Azetukalner NDA Submitted, EMA Gives Approval Recommendation to Ocrelizumab, Phase 3 FUSION Trial Meets End Points
2
What's Next in Ataxia: Pipeline Overview of Investigational Therapeutics
3
SKY-0515 Shows Sustained Benefit at 15 Months in Huntington Disease
4
FDA Extends Relutrigine Review, Delays PDUFA to December
5